AbbVie’s Investments In Cloud And High Performance Computing Are Increasing Efficiency And Breaking Down Barriers

AbbVie is a research-based, global biopharmaceutical company which discovers and delivers medicines and treatments across a range of disciplines including neuroscience, eye care, women’s health, and immunology.

In 2020, the company made a series of investments in cloud and high performance computing that enabled data science sophisticated enough to power automated bots to increase daily efficiency, and new data management ecosystems to break down barriers between solutions.

In 2021, AbbVie is building a team tasked with creating a data and knowledge platform that will assist the company in deploying artificial intelligence (AI) in its scientific research. Combining the mindset of a technology start-up with the patient-centric culture of AbbVie, the company is incorporating 3D and 4D imaging data into its application of deep learning algorithms in classification and segmentation, and exploring the application of quantum computing to the drug discovery process.


Subscribe to the Free LogiPharma Newsletter

Thanks for signing up! We'll let you know whenever a new article is published.

We respect your privacy, by clicking 'Submit' you will receive our e-newsletter, including information on Webinars, event discounts, online learning opportunities and agree to our User Agreement. You have the right to object. For further information on how we process and monitor your personal data, and information about your privacy and opt-out rights, click here.

Return to Blog